Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ACAD |
---|---|---|
09:32 ET | 10417 | 15.41 |
09:34 ET | 770 | 15.465 |
09:36 ET | 300 | 15.5 |
09:38 ET | 5036 | 15.5 |
09:39 ET | 2050 | 15.53 |
09:41 ET | 23800 | 15.57 |
09:43 ET | 4701 | 15.59 |
09:45 ET | 2475 | 15.6198 |
09:48 ET | 2230 | 15.62 |
09:50 ET | 2572 | 15.66 |
09:52 ET | 3423 | 15.61 |
09:54 ET | 4312 | 15.67 |
09:56 ET | 2593 | 15.7 |
09:57 ET | 502 | 15.705 |
09:59 ET | 100 | 15.72 |
10:01 ET | 2775 | 15.71 |
10:03 ET | 900 | 15.72 |
10:06 ET | 7993 | 15.8 |
10:08 ET | 2723 | 15.82 |
10:10 ET | 813 | 15.89 |
10:12 ET | 4441 | 15.93 |
10:14 ET | 3538 | 15.98 |
10:15 ET | 3100 | 15.89 |
10:17 ET | 1000 | 15.89 |
10:19 ET | 2400 | 15.83 |
10:21 ET | 2050 | 15.82 |
10:24 ET | 10407 | 15.83 |
10:26 ET | 2100 | 15.805 |
10:28 ET | 1180 | 15.79 |
10:30 ET | 3542 | 15.85 |
10:32 ET | 4560 | 15.8176 |
10:33 ET | 200 | 15.84 |
10:35 ET | 2833 | 15.88 |
10:37 ET | 2438 | 15.88 |
10:39 ET | 7546 | 15.97 |
10:42 ET | 3059 | 15.93 |
10:44 ET | 440 | 15.95 |
10:46 ET | 525 | 15.95 |
10:48 ET | 3145 | 15.92 |
10:50 ET | 1552 | 15.91 |
10:51 ET | 400 | 15.91 |
10:53 ET | 1514 | 15.91 |
10:55 ET | 4087 | 15.855 |
10:57 ET | 9689 | 15.915 |
11:00 ET | 2411 | 15.96 |
11:02 ET | 800 | 15.94 |
11:04 ET | 1409 | 15.94 |
11:06 ET | 455 | 15.95 |
11:08 ET | 7079 | 15.99 |
11:09 ET | 700 | 15.98 |
11:11 ET | 1600 | 15.93 |
11:13 ET | 1435 | 15.925 |
11:15 ET | 200 | 15.92 |
11:18 ET | 1296 | 15.935 |
11:20 ET | 1100 | 15.91 |
11:22 ET | 1970 | 15.88 |
11:24 ET | 1800 | 15.86 |
11:26 ET | 1502 | 15.9 |
11:27 ET | 1600 | 15.9 |
11:29 ET | 1155 | 15.91 |
11:31 ET | 616 | 15.92 |
11:33 ET | 200 | 15.91 |
11:36 ET | 1300 | 15.915 |
11:38 ET | 560 | 15.93 |
11:40 ET | 240 | 15.945 |
11:42 ET | 100 | 15.945 |
11:44 ET | 2314 | 15.95 |
11:45 ET | 1250 | 15.95 |
11:47 ET | 1040 | 15.98 |
11:49 ET | 4412 | 15.98 |
11:51 ET | 1721 | 15.98 |
11:54 ET | 1433 | 15.95 |
11:56 ET | 3340 | 15.995 |
11:58 ET | 4373 | 15.95 |
12:00 ET | 600 | 15.94 |
12:02 ET | 600 | 15.9 |
12:03 ET | 838 | 15.93 |
12:05 ET | 1600 | 15.92 |
12:07 ET | 517 | 15.92 |
12:09 ET | 3706 | 15.902 |
12:12 ET | 849 | 15.91 |
12:14 ET | 454 | 15.915 |
12:16 ET | 2349 | 15.91 |
12:18 ET | 865 | 15.91 |
12:20 ET | 700 | 15.915 |
12:21 ET | 735 | 15.91 |
12:23 ET | 200 | 15.9 |
12:25 ET | 500 | 15.915 |
12:27 ET | 2305 | 15.9 |
12:30 ET | 1262 | 15.91 |
12:32 ET | 3160 | 15.915 |
12:34 ET | 1450 | 15.91 |
12:36 ET | 100 | 15.9 |
12:38 ET | 800 | 15.89 |
12:39 ET | 2642 | 15.905 |
12:41 ET | 4855 | 15.94 |
12:43 ET | 979 | 15.925 |
12:45 ET | 1000 | 15.93 |
12:48 ET | 400 | 15.931 |
12:50 ET | 1103 | 15.96 |
12:52 ET | 500 | 15.95 |
12:54 ET | 100 | 15.95 |
12:56 ET | 1543 | 15.96 |
12:57 ET | 1200 | 15.955 |
12:59 ET | 200 | 15.95 |
01:01 ET | 1600 | 15.94 |
01:03 ET | 4679 | 15.92 |
01:06 ET | 11213 | 15.975 |
01:08 ET | 940 | 15.97 |
01:10 ET | 1200 | 15.97 |
01:12 ET | 1885 | 15.95 |
01:14 ET | 400 | 15.94 |
01:15 ET | 554 | 15.94 |
01:17 ET | 2396 | 15.945 |
01:19 ET | 1151 | 15.94 |
01:21 ET | 1084 | 15.98 |
01:24 ET | 300 | 15.97 |
01:26 ET | 900 | 16 |
01:28 ET | 1716 | 15.99 |
01:30 ET | 300 | 15.98 |
01:32 ET | 200 | 15.98 |
01:33 ET | 1150 | 15.96 |
01:35 ET | 4503 | 15.98 |
01:37 ET | 902 | 16 |
01:39 ET | 650 | 16 |
01:42 ET | 1023 | 16 |
01:44 ET | 5695 | 16.025 |
01:46 ET | 300 | 16.025 |
01:48 ET | 900 | 16.02 |
01:50 ET | 600 | 16.01 |
01:51 ET | 200 | 16.02 |
01:53 ET | 700 | 16.02 |
01:55 ET | 400 | 16.03 |
01:57 ET | 2189 | 16.04 |
02:00 ET | 1700 | 16.04 |
02:02 ET | 1068 | 16.03 |
02:04 ET | 200 | 16.04 |
02:06 ET | 3428 | 16.1 |
02:08 ET | 3594 | 16.08 |
02:09 ET | 300 | 16.08 |
02:11 ET | 700 | 16.08 |
02:13 ET | 1359 | 16.06 |
02:15 ET | 900 | 16.04 |
02:20 ET | 1645 | 16.06 |
02:22 ET | 703 | 16.065 |
02:24 ET | 1400 | 16.07 |
02:26 ET | 600 | 16.065 |
02:27 ET | 1232 | 16.07 |
02:29 ET | 2583 | 16.07 |
02:31 ET | 800 | 16.055 |
02:33 ET | 4617 | 16.065 |
02:36 ET | 1601 | 16.08 |
02:38 ET | 856 | 16.07 |
02:40 ET | 1789 | 16.08 |
02:42 ET | 2113 | 16.08 |
02:44 ET | 600 | 16.075 |
02:45 ET | 2052 | 16.07 |
02:47 ET | 513 | 16.07 |
02:49 ET | 400 | 16.09 |
02:51 ET | 631 | 16.085 |
02:54 ET | 1300 | 16.085 |
02:56 ET | 4208 | 16.12 |
02:58 ET | 2504 | 16.09 |
03:00 ET | 1000 | 16.07 |
03:02 ET | 300 | 16.05 |
03:03 ET | 400 | 16.04 |
03:05 ET | 2954 | 16.05 |
03:07 ET | 10667 | 16.11 |
03:09 ET | 2120 | 16.14 |
03:12 ET | 2828 | 16.155 |
03:14 ET | 250 | 16.15 |
03:16 ET | 400 | 16.15 |
03:18 ET | 1509 | 16.16 |
03:20 ET | 3879 | 16.13 |
03:21 ET | 894 | 16.14 |
03:23 ET | 3456 | 16.17 |
03:25 ET | 200 | 16.17 |
03:27 ET | 2485 | 16.15 |
03:30 ET | 3118 | 16.15 |
03:32 ET | 600 | 16.13 |
03:34 ET | 2144 | 16.14 |
03:36 ET | 5570 | 16.14 |
03:38 ET | 1499 | 16.12 |
03:39 ET | 3927 | 16.135 |
03:41 ET | 2601 | 16.145 |
03:43 ET | 10638 | 16.16 |
03:45 ET | 476 | 16.16 |
03:48 ET | 5243 | 16.175 |
03:50 ET | 4335 | 16.17 |
03:52 ET | 10164 | 16.185 |
03:54 ET | 5384 | 16.185 |
03:56 ET | 14043 | 16.17 |
03:57 ET | 16656 | 16.155 |
03:59 ET | 29169 | 16.13 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ACADIA Pharmaceuticals Inc | 2.7B | -1,253.3x | --- |
Azenta Inc | 2.8B | -19.1x | --- |
PTC Therapeutics Inc | 2.4B | -4.0x | --- |
Guardant Health Inc | 3.5B | -7.3x | --- |
Amicus Therapeutics Inc | 3.0B | -20.3x | --- |
Novavax Inc | 1.7B | -3.7x | --- |
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $813.8M |
Shares Outstanding | 165.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $-0.01 |
Book Value | $2.62 |
P/E Ratio | -1,253.3x |
Price/Sales (TTM) | 3.3 |
Price/Cash Flow (TTM) | 298.0x |
Operating Margin | -0.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.